Literature DB >> 27194846

Digital gangrene in a child with atypical hemolytic uremic syndrome associated with anti-factor H antibodies.

K P Sathe1, A Ohri1, A Mishra1, U Ali1.   

Abstract

Entities:  

Year:  2016        PMID: 27194846      PMCID: PMC4862277          DOI: 10.4103/0971-4065.169557

Source DB:  PubMed          Journal:  Indian J Nephrol        ISSN: 0971-4065


× No keyword cloud information.
Sir, A 10-year-old boy presented with generalized edema, pallor, dark colored urine, jaundice, vomiting, and abdominal pain for 5 days without preceding fever or bleeding manifestations. Hemoglobin was 6.3 g/dl, platelet count 0.72 × 103/µL, total leukocyte count 8000/µL, with abundant schistocytes on peripheral smear. He had retic count 3%, depressed serum haptoglobin, normal G6PD, and negative direct Coomb's test. Prothrombin time, activated partial thromboplastin time and fibrinogen levels were normal. D-Dimer was mildly elevated. Urinalysis revealed albumin 3+ and, 18–20 pus cells/hpf. Urine was strongly positive for hemoglobin. Biochemistry suggested blood urea nitrogen 150 mg/dl, serum creatinine 3.9 mg/dl, serum aspartate aminotransferase 210 U/L, serum alanine transaminase 110 U/L, serum bilirubin 3.3 mg/dl, direct bilirubin 1.1 mg/dl, serum lactate dehydrogenase 13,610 U/L, serum uric acid 12 mg/dl, and serum complement (C3) 53 mg/dl. Malarial parasites on peripheral smear, leptospira IgM, human immunodeficiency virus, hepatitis B surface antigen, and anti-hepatitis C virus was negative. Tests for anti-nuclear antibody, anti-double stranded DNA, antiphospholipid antibody, and anti-neutrophil cytoplasmic antibody were negative. Ultrasound revealed normal sized kidneys. Anti-factor H antibody level was elevated at 2,900 AU/mL (normal <150 AU). The diagnosis was consistent with atypical hemolytic uremic syndrome (HUS). He progressively developed oliguria, malignant hypertension with painful duskiness of all digits of all 4 limbs. There was no evidence of infective endocarditis and radial Doppler ultrasound ruled out vascular thrombosis. He was managed with daily single volume plasma exchange, hemodialysis and immunosuppression (6 doses of IV pulse dexamethasone at 5 mg/kg/dose and 3 doses of IVIG at 400 mg/kg/dose). The acral cyanosis progressed to frank gangrene [Figure 1] despite antiplatelet and anticoagulation therapy. He developed cardiac failure requiring inotropes and mechanical ventilation and later succumbed to the illness. Postmortem renal biopsy confirmed thrombotic microangiopathy (TMA).
Figure 1

Photograph of right hand showing duskiness of all digits progressing to frank gangrene

Photograph of right hand showing duskiness of all digits progressing to frank gangrene Our patient presented with HUS-TMA with anti-factor H antibodies. Anti-Factor H antibodies result in uncontrolled complement activation and have emerged as a major cause of HUS in the Indian subcontinent.[1] Although HUS can have extrarenal involvement in one-third of the cases, peripheral gangrene is extremely rare as the size of the vessels supplying the digits is relatively much larger than the microvasculature commonly affected in HUS.[23] Comorbid infections, vasculitis or prothrombotic disorders that can lead to digital gangrene were ruled out. The digital gangrene was thus attributed to persistent HUS activity. Eculizumab, a C5 blocking antibody that has been found effective in salvaging such cases,[2] could not be offered due to unaffordability. There are only seven reported cases of peripheral gangrene in association with HUS including only one case in association with anti-factor H antibody. The presentation of digital gangrene in HUS has been found to be associated with poor outcome with about 50% cases developing dialysis dependence and mortality despite aggressive management.[12345] Digital gangrene can thus result from malignant HUS activity and may portend a poor outcome.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  5 in total

1.  Peripheral gangrene in children with atypical hemolytic uremic syndrome.

Authors:  Michal Malina; Ashima Gulati; Arvind Bagga; Mohammad A Majid; Eva Simkova; Franz Schaefer
Journal:  Pediatrics       Date:  2012-12-10       Impact factor: 7.124

2.  Peripheral gangrene complicating idiopathic and recessive hemolytic uremic syndromes.

Authors:  B S Kaplan; C D Garcia; R W Chesney; W E Segar; K Giugno; R Chem
Journal:  Pediatr Nephrol       Date:  2000-09       Impact factor: 3.714

3.  Peripheral gangrene complicating hemolytic uremic syndrome in a child.

Authors:  Ahmet Ozel; Umran Calişkan; Safak Gücer
Journal:  Pediatr Nephrol       Date:  2003-03-28       Impact factor: 3.714

4.  Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children.

Authors:  Aditi Sinha; Ashima Gulati; Savita Saini; Caroline Blanc; Aarti Gupta; Bahadur Singh Gurjar; Himanshi Saini; Shambhuprasad T Kotresh; Uma Ali; Divya Bhatia; Alpana Ohri; Manish Kumar; Indira Agarwal; Sanjeev Gulati; Kanav Anand; M Vijayakumar; Rajiv Sinha; Sidharth Sethi; Maud Salmona; Anna George; Vineeta Bal; Geetika Singh; Amit K Dinda; Pankaj Hari; Satyajit Rath; Marie-Agnes Dragon-Durey; Arvind Bagga
Journal:  Kidney Int       Date:  2013-10-02       Impact factor: 10.612

5.  Atypical haemolytic uremic syndrome complicated by microangiopathic antiphospholipid-associated syndrome.

Authors:  A Meglic; S Grosek; M Benedik-Dolnicar; T Avcin
Journal:  Lupus       Date:  2008-09       Impact factor: 2.911

  5 in total
  1 in total

Review 1.  Eculizumab reversed severe distal ischemic syndrome and glomerulonephritis with isolated C3 deposits associated with anti-factor H autoantibodies: a case report.

Authors:  Samuel Deshayes; Nicolas Martin Silva; Valérie Chatelet; Sylvain Chantepie; Moglie Le Quintrec; François Comoz; Frank Bridoux; Marie-Agnès Dragon-Durey; Achille Aouba
Journal:  Clin Rheumatol       Date:  2018-03-07       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.